Hair Loss on Ozempic, Wegovy and Mounjaro: Why It Happens and What Recovers

Who This Is For#

This guide is for you if:

• You started semaglutide, tirzepatide or liraglutide for weight or blood sugar and your hair is shedding more than usual
• You are losing weight quickly by any route and want to know whether the hair loss is connected
• You want the rates that were actually reported, not forum anecdotes
• You want to know which blood tests are worth asking for before you buy a supplement
• You are trying to work out whether this needs your prescriber, a dermatologist, or time

This guide is NOT for you if:

• Your hair is coming out in round, smooth, bald patches: read Alopecia Areata
• Your scalp is red, scaly, painful or scarred where the hair has gone: read Scarring Alopecia
• Your thinning is concentrated at the part line and crown and was there before the drug: read Female Pattern Hair Loss: Treatment Options
• Your shedding followed a pregnancy rather than weight loss: read Hair Loss After Pregnancy

How Common Is Hair Loss on GLP-1 Drugs?#

What the Wegovy label reports#

The Wegovy (semaglutide) prescribing information is the only GLP-1 label in our research package that gives percentages for hair loss [1]. The figures come from its weight-management trials and are split by dose and by sex.

Two things stand out. The gap between women and men is wide at every dose: 4% of women against 0.9% of men on 2.4 mg, and 8.4% against 0.2% on 7.2 mg [1]. And the rate climbs with dose. The label does not guess at why. It says plainly that "hair loss adverse reactions in WEGOVY injection-treated patients were associated with weight reduction" [1].

A note on Ozempic. Ozempic is the same molecule, semaglutide, carrying a separate label for diabetes. That label was not part of our review, so the percentages above are Wegovy weight-management figures, not Ozempic-specific ones. Given that the label ties hair loss to weight reduction, the amount of weight lost is likely to matter more than which box the pen came in, but that is an inference, not a measured rate.

What the pooled trials show#

The most direct evidence is a systematic review and meta-analysis by Cheng and Chang, which pooled nine interventional studies (7 RCTs and 2 non-RCTs) with data from 4114 GLP-1 receptor agonist users [3]. It found "a significantly higher risk of hair loss in GLP-1 RA users than in placebo users (risk ratio [RR]: 3.252; 95% CI: 1.437 to 7.358)", and reported that "the hair loss event rate following GLP-1 RA therapy was 3.9%" [3].

Read the confidence interval, not just the point estimate. An interval running from 1.437 to 7.358 means the risk is clearly above placebo but its size is not well pinned down. The absolute event rate of 3.9% is the more useful number for an individual: most people on these drugs do not report hair loss [3].

A separate systematic review by Gupta and colleagues screened 133 studies and included 24, and concluded there is "an increased risk of hair loss with certain GLP-1 RAs, particularly semaglutide and tirzepatide" [4]. A scoping review by Rojas Lopez and colleagues adds that "more than 1,000 spontaneous cases have been reported in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)" [5]. Spontaneous reports are a signal, not a rate: they have no denominator and cannot tell you how likely the problem is for any given patient.

Mounjaro, Ozempic and liraglutide: where the numbers run out#

The Mounjaro (tirzepatide) label lists alopecia only under postmarketing experience, as "Skin and Subcutaneous Tissue: alopecia", with no percentage attached [2]. So there is no label-derived rate to quote for tirzepatide. What the reviews say is qualitative: "Tirzepatide, associated with the greatest magnitude of weight loss, was most frequently linked to telogen effluvium" [4]. That fits the weight-loss explanation rather than contradicting it.

Liraglutide (Saxenda, Victoza) appears among the drugs covered in the scoping literature [5], but our package contains no verified liraglutide-specific rate. We are not going to print one.

Why It Happens: Telogen Effluvium, Not Follicle Damage#

A trigger, not a toxin#

None of the sources we reviewed describes a receptor-level or direct toxic effect of these drugs on the hair follicle. Every mechanistic account frames the shedding as secondary to weight loss. Burke and colleagues, reviewing the dermatologic effects of GLP-1 receptor agonists, put it this way: "hair loss, particularly in the form of telogen effluvium, has been observed, potentially linked to rapid weight loss" [6].

Telogen effluvium is worth understanding properly, because it changes what you should expect. Yorulmaz and colleagues, in a case series of 3028 patients, define it as "a common form of non-scarring alopecia, characterized by excessive shedding of telogen club hairs" [8]. Each follicle cycles between a long growth phase and a short resting (telogen) phase, and normally only a small fraction of follicles rest at any moment. A systemic jolt, such as a sudden energy and protein shortfall, pushes an unusually large share of follicles into rest at the same time. They sit there, then release their hairs together. The result is diffuse shedding across the whole scalp, with a widening part and a thinner ponytail rather than bald spots. Because it is non-scarring, the follicle itself is preserved [8].

The closest analogy is bariatric surgery, a far larger and faster weight-loss stimulus than any injection. A meta-analysis by Zhang and colleagues found that "the incidence of hair loss after MBS was 57% (95% CI 42-71%)", that it was more common in younger patients and in women, and that serum zinc, folic acid and ferritin levels correlated with it [10]. That figure is not a GLP-1 figure and should not be read as one, but it shows what a severe version of the same process looks like.

How much and how fast#

The one study in our package that puts numbers on the weight-loss trigger is a single-center retrospective series from Kang and colleagues. They report that "TE induced by weight loss occurred at a mean weight loss percentage and mean weight loss rate of approximately 15.21% and 3.54 kg/months" [7]. This was not a GLP-1 cohort, and the figures are averages among people who did develop telogen effluvium, not a threshold below which you are safe. But the message is consistent with everything else here: magnitude and pace of loss drive the shedding.

Dose matters because weight loss does#

Gupta and colleagues note that "hair loss associated with semaglutide appeared to be dose-dependent, with doses < 2mg weekly rarely implicated while higher obesity-treatment doses were more commonly associated with hair loss" [4]. That is a qualitative synthesis rather than a pooled statistic, but it lines up with the Wegovy label's own within-drug comparison of 3.3% at 2.4 mg against 5.8% at 7.2 mg [1]. Higher doses produce more weight loss, and more weight loss produces more telogen effluvium. The drug is the cause of the weight loss; the weight loss is the cause of the shedding.

One more mechanism deserves a mention because it is easy to miss. Appetite suppression is the point of these drugs, and total food intake falls. If protein intake falls with it, the hair follicle, one of the most rapidly dividing tissues in the body, is among the first to economize. Our package does not contain a quantified protein target for people on GLP-1 therapy, so we will not invent one; see Protein Intake for Hair for the general evidence.

When It Starts and What Recovers#

Timing#

None of the sources in our package gives a verified interval between starting the drug and the start of shedding, so we will not print one. What can be said is qualitative. Telogen effluvium lags its trigger, because follicles first have to shift into the resting phase and then complete that rest before the hair drops. In practice this means shedding tends to show up after weight has already been coming off for a while, often around the time the dose has been stepped up, rather than in the first days of treatment. If your shedding began the week you started, look for another trigger too.

The useful thing to do at this stage is measure rather than worry. Photograph your part line and hairline under the same light each month, and use the shedding check to get a rough sense of whether what you are seeing is beyond normal daily loss. See Tracking Progress with Photos for a method that works.

What recovers, and what the evidence does not tell you#

Because telogen effluvium is non-scarring [8], the follicles that shed are still there and still capable of producing hair. That is the single most reassuring fact in this guide, and it is well supported. What is not well supported, at least in our package, is a specific recovery timeline. The standard dermatologic teaching is that telogen effluvium settles once its trigger settles, but we could not verify a "regrowth by month X" claim against a quotable source, so we are not printing one. Anyone who gives you a confident month count is working from experience, not from the trial data.

What "the trigger settling" means here is concrete: weight stabilizing rather than continuing to fall quickly, and energy and protein intake being adequate for your new weight. Both of those are things to work on with the prescriber, not against them.

Two complications are worth knowing. First, the case literature is not all telogen effluvium; the scoping reviews also contain reports of pattern hair loss in people on these drugs [5]. A telogen shed can unmask underlying female pattern hair loss that was already there, and that component does not resolve on its own. If your shedding slows but the part keeps widening, read Diffuse Thinning vs Pattern Baldness. Second, if a nutritional deficit is now part of the picture, the shed can persist until it is corrected, which is why the next section matters.

Nutritional Checks Worth Asking For#

Ferritin and iron#

Ferritin is the test with the strongest real-world claim to relevance. In the Yorulmaz series of 3028 telogen effluvium patients, serum ferritin was the most frequently ordered laboratory test, performed in 82.3% of patients, and "iron replacement therapy represented the most common treatment at 37.5% of prescriptions" [8]. In a case-control study of 250 women with telogen effluvium and 250 healthy controls, ferritin was lower in the telogen effluvium group and the difference was statistically significant (P < 0.05); the authors conclude that "iron deficiency anemia is thought of as a factor in female patients with telogen effluvium" [9]. In the bariatric meta-analysis, ferritin was one of the serum markers that correlated with hair loss [10].

This matters more for women, who make up most of the GLP-1 hair-loss reports [1] and who are more likely to run low on iron in the first place. See Ferritin and Hair Loss and Iron Deficiency Hair Loss in Women for what the numbers on the result sheet mean.

Vitamin D, B12, zinc and folate#

The same large series found that "vitamin D deficiency appeared in 72.2% of screened individuals, with B12 deficiency at 30.7%" [8]. Those are prevalence figures among people already being worked up for telogen effluvium, not proof of causation, but they are high enough that checking is reasonable. Zinc and folic acid join ferritin as the markers correlated with hair loss after bariatric surgery [10], and a review of post-bariatric micronutrient deficiencies lists hair loss among their clinical manifestations and recommends periodic monitoring with individualized supplementation rather than guesswork [11].

One caution on zinc and vitamin D. A meta-analysis of 34 studies and 4,931 participants found lower serum vitamin D and zinc in people with alopecia areata [12]. Alopecia areata is an autoimmune condition, not telogen effluvium, and that finding must not be read as GLP-1-specific evidence. It is cited here only as general dermatologic support for the idea that these nutrients are relevant to hair.

Thyroid function is a standard part of any hair-loss workup even though it is not GLP-1-specific; see Thyroid Hair Loss. For the full request list, see Women's Hair Loss Blood Tests or run the blood test tool.

Protein and total intake#

This is the check that does not come on a lab form. Our package contains no study quantifying protein intake in GLP-1 users with hair loss, so the evidence here is thin and we will say so. The logic is simple, though: these drugs work by reducing appetite, and a reduced appetite does not automatically protect protein. If meals have shrunk to a few bites, it is worth asking the prescriber or a dietitian to look at what is actually being eaten. Best Diet for Hair Growth covers the general evidence.

When to See a Clinician#

Prescriber first, dermatologist for red flags#

The person who wrote the prescription is the first stop. They know the dose and the titration schedule, they can see how fast the weight is coming off, and they can order the blood work above in a single visit. Bring a rough estimate of the shedding, photographs, and a plain account of what you are eating in a day. The conversation to have is about pace, intake and testing, not about whether to quit.

A dermatologist is the right next step if the pattern does not fit a diffuse shed, or if anything about it looks wrong. Go promptly if you notice:

• Hair coming out in defined round or oval patches with smooth skin underneath
• Redness, scale, pustules, pain, burning or itching in the areas of loss
• Any area where the skin looks shiny or the follicle openings have disappeared
• Loss of eyebrow or body hair alongside scalp hair
• Fatigue, weight loss beyond what the drug was expected to produce, fever, joint pain or other systemic symptoms
• Shedding that continues to worsen well after weight has stabilized

Those features point away from telogen effluvium and toward conditions that need a diagnosis, some of them urgently. See When to See a Dermatologist.

What Not to Do#

The mistakes that cost people the most#

Do not stop or change the drug on your own. This is general clinical guidance rather than something any of our sources tested, but it is the point most worth making. These medicines are prescribed for weight, blood sugar and cardiometabolic reasons that do not go away because hair is shedding. Stopping abruptly can reverse the weight loss and, with it, whatever health gains prompted the prescription. If the shedding is intolerable, that is a legitimate thing to say to your prescriber, and a slower titration or a plan for intake is a conversation worth having with them. It is not a decision to make alone.

Do not supplement blind. Iron, zinc and vitamin D are all worth testing, and none of them should be taken at high doses without a result showing you need them. Iron accumulates; excess zinc interferes with copper; vitamin D at high doses is not benign. Test, then treat what is low. See Iron Supplements and Zinc and Hair Loss.

Do not treat a shed as pattern loss, or pattern loss as a shed. Starting minoxidil for what turns out to be a self-limiting telogen effluvium commits you to an indefinite treatment you may not have needed. Waiting out what turns out to be female pattern hair loss loses ground you will not get back. If the picture is unclear, get it examined.

Do not cut intake further to speed things up. Layering a restrictive diet on top of an appetite-suppressing drug is the surest way to deepen the deficit that caused the shed.

Do not expect the label numbers to apply to you as odds. A 3.3% rate at 2.4 mg [1] describes a trial population. Your own risk depends on how much you lose, how fast, what you eat while doing it, and what your ferritin was before you started.

Hair loss, even temporary hair loss, is distressing, and that distress is not vanity. If it is affecting how you feel about yourself, Emotional Impact of Hair Loss is written for exactly this.

Frequently Asked Questions#

Related Resources#

• Telogen Effluvium
• Ferritin and Hair Loss
• Women's Hair Loss Blood Tests
• Protein Intake for Hair
• Vitamin D and Hair Loss
• Diffuse Thinning vs Pattern Baldness
• When to See a Dermatologist
• Women's Hair Loss: The Complete Guide